Pathologic Concordance of Sporadic Synchronous Bilateral Renal Masses

Rothman, Jason; Crispen, Paul L.; Wong, Yu‐Ning; Al‐Saleem, Tahseen; Fox, Eric; Uzzo, Robert G.

doi:10.1016/j.urology.2008.01.043

Cited by 42 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bilateral synchronous renal tumors have been evaluated in many studies [2–4]. Patel et al [17] more recently found that malignant concordance was 89% among the patients who had bilateral synchronous renal tumors.…”

Section: Discussionmentioning

confidence: 99%

Coexisting Papillary and Clear Renal Cell Carcinoma in the Same Kidney

Üstüner

Yaprak

Teke

et al. 2014

Case Reports in Urology

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common solid lesion of the kidney. Bilateral synchronous benign and malignant renal tumors have been defined in some reports. However, unilateral concordance of malignant renal tumors is very rare and there are only a few cases that had synchronous different subtypes of malignant renal tumors arising within the same kidney. Herein, we describe a 67-year-old male patient who had clear cell RCC and papillary RCC in his right kidney that were successfully treated with radical nephrectomy. We also reviewed the pertinent literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Coexisting Papillary and Clear Renal Cell Carcinoma in the Same Kidney

Üstüner

Yaprak

Teke

et al. 2014

Case Reports in Urology

View full text Add to dashboard Cite

show abstract

“…14 Earlier efforts to define pathological concordance rates of renal tumors focused primarily on cases of sporadic BSRMs. 6,7,16,17 In the largest report of BSRMs analyzing malignant, histological and grade concordance Rothman et al noted a rate of 99%, 93% and 83%, respectively, in a review of SEER data. 7 More recently, in a single institution retrospective account Patel et al reported similarly high rates of malignant concordance in 89% of patients who presented with BSRMs.…”

Section: Discussionmentioning

confidence: 99%

“…6,7,16,17 In the largest report of BSRMs analyzing malignant, histological and grade concordance Rothman et al noted a rate of 99%, 93% and 83%, respectively, in a review of SEER data. 7 More recently, in a single institution retrospective account Patel et al reported similarly high rates of malignant concordance in 89% of patients who presented with BSRMs. 8 In contrast to bilateral renal masses, our examination of unilateral synchronous multifocal disease revealed a much lower malignant concordance rate of 77.2%.…”

Section: Discussionmentioning

confidence: 99%

Pathological Concordance and Surgical Outcomes of Sporadic Synchronous Unilateral Multifocal Renal Masses Treated with Partial Nephrectomy

et al. 2013

Self Cite

View full text Add to dashboard Cite

In what is to our knowledge the largest published report of unilateral synchronous multifocal renal masses we document low pathological concordance rates. As such, percutaneous biopsy of a single renal mass in these patients may not help inform treatment decisions. Nephron sparing surgery may be performed with acceptable oncological and functional results in patients with unilateral synchronous multifocal renal masses.

show abstract

“…19 Although some clinicians advocate the use of percutaneous biopsy in the majority of patients for risk stratification, others selectively use renal biopsy in patients with absolute or relative indications or specific circumstances where nephron preservation is paramount such as synchronous bilateral lesions. 20 …”

Section: Discussionmentioning

confidence: 99%

Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?

Mehrazin¹,

Smaldone²,

Egleston³

et al. 2015

Urologic Oncology: Seminars and Original Investigations

Self Cite

View full text Add to dashboard Cite

Introduction Linear growth rate (LGR) is the most commonly employed trigger for definitive intervention in patients with renal masses managed with an initial period of active surveillance (AS). Using our institutional cohort, we explored the association between tumor anatomic complexity at presentation and LGR in patients managed with AS. Methods and Materials Enhancing renal masses managed expectantly for at least 6 months were included for analysis. The association between NS and LGR was assessed using generalized estimating equations, adjusting for age, Charlson score, race, sex, and initial tumor size. Results 346 patients (401 masses) met inclusion criteria (18% ≥cT1b), with a median follow-up of 37 months (range: 6-169). 44% of patients progressed to definitive intervention with a median duration of 27 months (range: 6-130). Comparing patients managed expectantly to those requiring intervention, no difference was seen in median tumor size at presentation (2.2 vs. 2.2 cm), while significant differences in median age (74 vs. 65 years, p<0.001), Charlson co-morbidity score (3 vs. 2, p<0.001), and average LGR (0.23 vs. 0.49 cm/year, p<0.001) were observed between groups. Following adjustment, for each 1-point increase in NS sum, the average tumor LGR increased by 0.037 cm/year (p=0.002). Of the entire cohort, 6 patients (1.7%) progressed to metastatic disease. Conclusions The demonstrated association between anatomic tumor complexity at presentation and LGR of clinical stage 1 renal masses under AS may afford a clinically useful cue to tailor individual patient radiographic surveillance schedules and warrants further evaluation.

show abstract

Pathologic Concordance of Sporadic Synchronous Bilateral Renal Masses

Cited by 42 publications

References 30 publications

Coexisting Papillary and Clear Renal Cell Carcinoma in the Same Kidney

Coexisting Papillary and Clear Renal Cell Carcinoma in the Same Kidney

Pathological Concordance and Surgical Outcomes of Sporadic Synchronous Unilateral Multifocal Renal Masses Treated with Partial Nephrectomy

Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?

Contact Info

Product

Resources

About